News & Updates
Filter by Specialty:
Add-on docetaxel confers survival advantage in ICI-naïve NSCLC, with caveat
In the treatment of patients with ICI-naïve nonsmall cell lung cancer (NSCLC), adding the cytotoxic chemotherapy docetaxel to the immune-checkpoint inhibitor (ICI) nivolumab leads to a significantly longer survival, although at the expense of slightly elevated toxicity, according to the results of a phase II/III trial.
Add-on docetaxel confers survival advantage in ICI-naïve NSCLC, with caveat
20 Oct 2022
Circulating T cells tied to CVD risk in people with HIV infection
Subsets of peripheral circulating CD4 T cell among people with HIV infection (PWH) are predictive of incident cardiovascular disease (CVD), including heart failure and atherosclerotic CVD, reveals a study.
Circulating T cells tied to CVD risk in people with HIV infection
20 Oct 2022
Vitamin C may play protective role in metabolic disorders among overweight patients
Vitamin C appears to protect against metabolic disorders due to its close association with glucose-lipid metabolism in overweight and obese patients who are undergoing laparoscopic sleeve gastrectomy (LSG), according to a study. Moreover, LSG does not seem to worsen the vitamin C status or deficiency.
Vitamin C may play protective role in metabolic disorders among overweight patients
20 Oct 2022
Beta-blocker shows potential for diabetic foot ulcers
A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).
Beta-blocker shows potential for diabetic foot ulcers
20 Oct 2022
Smoking during pregnancy ups hypertension risk in offspring
Children exposed to maternal smoking during pregnancy have higher systolic blood pressure (SBP) and are at a heightened risk of hypertension, a recent study has found.
Smoking during pregnancy ups hypertension risk in offspring
20 Oct 2022
Pembrolizumab improves DFS in completely resected stage IB–IIIA NSCLC
Adjuvant pembrolizumab significantly improves disease-free survival (DFS) vs placebo in patients with completely resected, PD-L1–unselected, stage IB–IIIA non-small-cell lung cancer (NSCLC), a second interim analysis of the triple-blind phase III PEARLS/KEYNOTE-091 trial has shown.